Search - tctmd.com

Displaying 141 - 154 of 154

Sort: Relevancy | Date

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Daily News

Good Warfarin Management Prevents Complications in A-fib Patients, Swedish Study Contends

April 21, 2016

News Daily News

In the Real World, Dabigatran and Warfarin Give Equal Stroke Protection to A-fib Patients

January 25, 2016

News Daily News

研究肯定了 Watchman 左心耳封堵器减少卒中的成本效益

December 14, 2015

News Daily News

Un Estudio Confirma la Rentabilidad del Dispositivo Watchman para el Cierre del AAI en el Descenso de ACV

December 14, 2015

News Daily News

Study Affirms Cost-Effectiveness of Watchman LAA Closure Device for Stroke Reduction

December 14, 2015

News Daily News

首个 NOAC 逆转剂 Idarucizumab 获批；不太可能耽误介入治疗

October 26, 2015

News Daily News

First NOAC Antidote, Idarucizumab, Approved; Likely Won’t Hold Up Interventions

October 26, 2015

News Daily News

Aprobado el Idarucizumab, Primer Antídoto de NOAC; El Deseo es no Demorar las Intervenciones

October 26, 2015

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Industry News

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

June 26, 2015

News Industry News

One-Year Outcomes Data on Stroke Prevention in Patients With Newly Diagnosed Atrial Fibrillation (AF) to Be Presented at ISTH 2015

June 18, 2015

News Daily News

Pharmacists May Help Ameliorate Substantial Variation in Dabigatran Adherence

April 17, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.